Archives

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA

Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of AntiInflammatory Treatment for Cystic Fibrosis (CF)

Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial

Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately

Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA